Dario Strbenac
Dario Strbenac has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Jean Yee Hwa Yang
School of Mathematics and Statistics, The University of Sydney, Sydney, Australia
29 shared publications - Jonathan Robert Clark
Department of Head and Neck Surgery Chris O'Brien Lifehouse Sydney New South Wales Australia
20 shared publications - Ruta Gupta
Central Medical School, Faculty of Medicine and Health Sciences, The University of Sydney, Sydney, Australia
20 shared publications - Aji Istadi
Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia
19 shared publications - Carsten E. Palme
The Department of Head and Neck Surgery, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia
19 shared publications - Claude V. Dennis
AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia
19 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Comparison of Performance of Publicly Available Polygenic Risk Scores to Predict Clinically Actionable Coronary Artery Calcium Scores: The BioHEART-CT Cohort
AIM: Coronary artery disease (CAD) remains the leading cause of morbidity and mortality globally. Polygenic Risk Scores (PRS) have been trained against major adverse cardiovascular outcomes (MACE) in large cohorts. Few studies have examined the effectiveness of these CAD MACE PRS tools in detecting individuals with subclinical coronary calcification. An association would provide an opportunity for clinical translation and targeting of CT imaging to new patients at risk for subclinical disease. METHODS: An analysis of 53 publicly available CAD PRS tools was completed in participants of the BioHEART-CT Discovery 1000 cohort presenting for clinically referred CT coronary angiography (CCTA). Associations between PRS and two binary CACS outcomes reflecting clinically significant coronary calcification were assessed: a) Absolute CACS (CACS ≥100 Agatston units [AU]; and b) Percentile CACS (CACS ≥75th age-/sex-adjusted percentile). Models were adjusted for genetic principal components, modifiable cardiovascular risk factors, and age/sex (in Absolute CACS). A subgroup analysis was performed using Framingham Risk Score (FRS) at baseline. RESULTS: Among 803 BioHEART-CT Discovery 1000 participants, 487 (60.6%) had any detectable coronary calcium. Most PRS tools demonstrated significant association with CACS outcomes, particularly evident when PRS was modelled as a continuous predictor. For Percentile CACS, 94.3% of PRS tools were significantly associated after full adjustment (median OR per PRS SD 1.41 (IQR 1.23-1.60). Quintile-based analysis revealed that individuals in the Top Quintile PRS had up to 7.99-fold increased odds of Percentile CACS ≥75th compared to those in the Bottom Quintile. Analysis by FRS group revealed positive performance, especially in individuals of Low FRS wherein incorporating a PRS increased pre-test probability from 14% to 26%. CONCLUSION: Whilst most CAD PRS tools have been developed against clinical events, we show their ability to predict clinically relevant coronary calcification. Utility appears strongest in individuals traditionally considered lower risk, presenting an opportunity for clinical translation for improved diagnosis in the primary prevention setting, with the potential to triage individuals into a CACS screening pathway.
- 16 September 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Open AccessComparison of Performance of Publicly Available Polygenic Risk Scores to Predict Clinically Actionable Coronary Artery Calcium Scores: The BioHEART-CT Cohort
AIM: Coronary artery disease (CAD) remains the leading cause of morbidity and mortality globally. Polygenic Risk Scores (PRS) have been trained against major adverse cardiovascular outcomes (MACE) in large cohorts. Few studies have examined the effectiveness of these CAD MACE PRS tools in detecting individuals with subclinical coronary calcification. An association would provide an opportunity for clinical translation and targeting of CT imaging to new patients at risk for subclinical disease. METHODS: An analysis of 53 publicly available CAD PRS tools was completed in participants of the BioHEART-CT Discovery 1000 cohort presenting for clinically referred CT coronary angiography (CCTA). Associations between PRS and two binary CACS outcomes reflecting clinically significant coronary calcification were assessed: a) Absolute CACS (CACS ≥100 Agatston units [AU]; and b) Percentile CACS (CACS ≥75th age-/sex-adjusted percentile). Models were adjusted for genetic principal components, modifiable cardiovascular risk factors, and age/sex (in Absolute CACS). A subgroup analysis was performed using Framingham Risk Score (FRS) at baseline. RESULTS: Among 803 BioHEART-CT Discovery 1000 participants, 487 (60.6%) had any detectable coronary calcium. Most PRS tools demonstrated significant association with CACS outcomes, particularly evident when PRS was modelled as a continuous predictor. For Percentile CACS, 94.3% of PRS tools were significantly associated after full adjustment (median OR per PRS SD 1.41 (IQR 1.23-1.60). Quintile-based analysis revealed that individuals in the Top Quintile PRS had up to 7.99-fold increased odds of Percentile CACS ≥75th compared to those in the Bottom Quintile. Analysis by FRS group revealed positive performance, especially in individuals of Low FRS wherein incorporating a PRS increased pre-test probability from 14% to 26%. CONCLUSION: Whilst most CAD PRS tools have been developed against clinical events, we show their ability to predict clinically relevant coronary calcification. Utility appears strongest in individuals traditionally considered lower risk, presenting an opportunity for clinical translation for improved diagnosis in the primary prevention setting, with the potential to triage individuals into a CACS screening pathway.
- Open Access
- 1 August 2026
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1)
Machine learning image analysis predicts Parkinson disease genotype and mitochondrial lysosomal abnormalities in iPS neurons
Mitochondrial and lysosomal dysfunction are central features of Parkinson’s disease (PD) across major genetic forms including PRKN , SNCA , and LRRK2 . We applied cell morphomics , a machine-learning-based framework combining high-content imaging with quantitative feature extraction, to analyse mitochondrial and lysosomal morphology at single-cell resolution in iPS cell-derived cortical neurons from PD patients and healthy controls (13 lines total). Supervised machine-learning models distinguished PD neurons from controls with high accuracy (AUC = 0.87) and reliably separated individual genotypes. Feature importance and attribution analysis revealed genotype-specific organelle biases in the relative contribution of mitochondrial and lysosomal features, with mitochondrial features dominating classification in PRKN neurons, balanced mitochondrial and lysosomal contributions in SNCA neurons, and a greater lysosomal contribution in LRRK2 neurons. Multi-class models retained strong performance, and findings were reproduced across two independent laboratories using different dyes and imaging conditions. These results demonstrate that morphomics provides a robust and scalable framework to quantify genotype-specific organelle abnormalities in PD neurons and supports its application for cellular stratification and biomarker discovery.
- 1 August 2026
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1)
Open AccessMachine learning image analysis predicts Parkinson disease genotype and mitochondrial lysosomal abnormalities in iPS neurons
Mitochondrial and lysosomal dysfunction are central features of Parkinson’s disease (PD) across major genetic forms including PRKN , SNCA , and LRRK2 . We applied cell morphomics , a machine-learning-based framework combining high-content imaging with quantitative feature extraction, to analyse mitochondrial and lysosomal morphology at single-cell resolution in iPS cell-derived cortical neurons from PD patients and healthy controls (13 lines total). Supervised machine-learning models distinguished PD neurons from controls with high accuracy (AUC = 0.87) and reliably separated individual genotypes. Feature importance and attribution analysis revealed genotype-specific organelle biases in the relative contribution of mitochondrial and lysosomal features, with mitochondrial features dominating classification in PRKN neurons, balanced mitochondrial and lysosomal contributions in SNCA neurons, and a greater lysosomal contribution in LRRK2 neurons. Multi-class models retained strong performance, and findings were reproduced across two independent laboratories using different dyes and imaging conditions. These results demonstrate that morphomics provides a robust and scalable framework to quantify genotype-specific organelle abnormalities in PD neurons and supports its application for cellular stratification and biomarker discovery.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Fig. S4 shows tumor growth curves from the in vivo study of the TKCC-IORMS-01 PDX model.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Fig. S4 shows tumor growth curves from the in vivo study of the TKCC-IORMS-01 PDX model.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Table S11 shows the effect of pairwise drug combinations on TKCC-IORMS-01 PDCL viability in drug synergy studies.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Table S11 shows the effect of pairwise drug combinations on TKCC-IORMS-01 PDCL viability in drug synergy studies.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Table S10 shows differentially expressed genes between TFCP2-rearranged RMS and other RMS subtypes.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Table S10 shows differentially expressed genes between TFCP2-rearranged RMS and other RMS subtypes.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Table S4 shows the copy number alterations identified in the IORMS-01 patient tumor and matched TKCC-IORMS-01 patient-derived cell line (PDCL).
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Table S4 shows the copy number alterations identified in the IORMS-01 patient tumor and matched TKCC-IORMS-01 patient-derived cell line (PDCL).
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S6 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Fig. S6 shows molecular effects of crizotinib in vivo, with IHC for Ki-67, CC3, HIF1α, pH2AX, CD31, and αSMA, and collagen structure analysis by Picrosirius Red staining and birefringence quantification.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S6 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Fig. S6 shows molecular effects of crizotinib in vivo, with IHC for Ki-67, CC3, HIF1α, pH2AX, CD31, and αSMA, and collagen structure analysis by Picrosirius Red staining and birefringence quantification.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Fig. S5 shows additikonal molecular analysis of tumors from the in vivo treatment study for LLY-283, dactolisib and the combination of LLY-283 and dactolisib, including IHC for CC3, HIF1α, p-H2AX, αSMA, and Picrosirius Red staining with birefringence imaging to assess ECM remodelling.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Fig. S5 shows additikonal molecular analysis of tumors from the in vivo treatment study for LLY-283, dactolisib and the combination of LLY-283 and dactolisib, including IHC for CC3, HIF1α, p-H2AX, αSMA, and Picrosirius Red staining with birefringence imaging to assess ECM remodelling.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Table S5 shows the point mutations identified in the IORMS-01 patient tumor and matched TKCC-IORMS-01 PDCL.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Table S5 shows the point mutations identified in the IORMS-01 patient tumor and matched TKCC-IORMS-01 PDCL.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Table S1 shows the agents used for in vitro drug sensitivity and synergy studies.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma
Supplementary Table S1 shows the agents used for in vitro drug sensitivity and synergy studies.